BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (down 68.52% YoY), and the FY2024 full-year result was $95.0 million, down 14.07% from the prior year.
• Change in Acquisitions & Divestments declined to $10.0 million in Q1 2026, from $31.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $443.1 million in Q3 2022 to a low of $3.0 million in Q2 2022.
• A 4-year average of $63.2 million and a median of $26.9 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments plunged 97.83% in 2022 and surged 675.44% in 2023, its largest moves.
• Tracing BBIO's Change in Acquisitions & Divestments over 4 years: stood at $26.9 million in 2022, then rose by 10.14% to $29.6 million in 2023, then climbed by 7.36% to $31.8 million in 2024, then plunged by 68.52% to $10.0 million in 2026.
• Business Quant data shows BBIO's Change in Acquisitions & Divestments at $10.0 million in Q1 2026, $31.8 million in Q4 2024, and $63.2 million in Q1 2024.